FDA’s Busiest Advisory Committee
This article was originally published in RPM Report
Executive Summary
The Anesthetic & Analgesic Drug Products Advisory Committee is scheduled for five days of meetings in the coming months – and FDA’s revised policy on opioids suggests that panel will be meeting a lot more often in the years to come.